RA
AMPH icon

Royce & Associates’s Amphastar Pharmaceuticals AMPH Stock Holding History

Royce & Associates’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.95M Sell
294,758
-111,417
-27% -$2.25M 0.05% 478
2026
Q1 		$7.96M Buy
406,175
+53,878
+15% +$1.32M 0.08% 388
2025
Q4 		$9.43M Sell
352,297
-14,025
-4% -$361K 0.1% 327
2025
Q3 		$9.76M Buy
366,322
+83,135
+29% +$2.15M 0.1% 307
2025
Q2 		$6.5M Buy
283,187
+35,329
+14% +$877K 0.07% 409
2025
Q1 		$7.19M Buy
247,858
+238,956
+2,684% +$7.63M 0.08% 375
2024
Q4 		$331K Sell
8,902
-174
-2% -$7.96K ﹤0.01% 784
2024
Q3 		$440K Hold
9,076
– – ﹤0.01% 807
2024
Q2 		$363K Buy
+9,076
New +$376K ﹤0.01% 813
2023
Q2 		– Sell
-22,315
Closed -$837K – 915
2023
Q1 		$837K Buy
+22,315
New +$732K 0.01% 787
2022
Q3 		– Sell
-13,546
Closed -$471K – 933
2022
Q2 		$471K Sell
13,546
-7,354
-35% -$262K ﹤0.01% 840
2022
Q1 		$750K Buy
20,900
+894
+4% +$25.4K 0.01% 836
2021
Q4 		$466K Buy
+20,006
New +$409K ﹤0.01% 899

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Royce & Associates's AMPH Position: Q2 2026 in Review

Royce & Associates reduced its Amphastar Pharmaceuticals (AMPH) stake by 27% in Q2 2026, selling an estimated $2.25M and leaving 294,758 shares worth $5.95M. The position accounts for 0.05% of the portfolio, ranked #478.

Royce & Associates first reported a position in AMPH in Q4 2021 and has held it in 13 quarters since. The position peaked at $9.76M in Q3 2025. 210 funds tracked by Wall St. Rank hold AMPH as of Q2 2026.

  • Royce & Associates held 294,758 shares of Amphastar Pharmaceuticals worth $5.95M as of Q2 2026.
  • Royce & Associates sold 111,417 Amphastar Pharmaceuticals shares in Q2 2026, an estimated $2.25M.
  • Amphastar Pharmaceuticals made up 0.05% of Royce & Associates's portfolio in Q2 2026, its #478 holding.
  • Royce & Associates first reported a position in Amphastar Pharmaceuticals in Q4 2021 and has held it in 13 quarters since.
  • Royce & Associates's Amphastar Pharmaceuticals position peaked at $9.76M in Q3 2025.
  • 210 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.